Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) or chemoradiotherapy (CRT) is the standard of care for patients with muscle invasive bladder cancer (MIBC). Mutations ...

Specifically, mutations in one or more of ATM, RB1, FANCC, and ERCC2 are associated with pathologic response or pCR at the time of cystectomy and predict improved progression-free (PFS ...

Biological evolution is, however, marked by compelling mutations that escape the watchful ... double-stand break; ERCC2, xeroderma pigmentosum complementing protein D; ERCC3, xeroderma pigmentosum ...